Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Amphista Therapeutics Limited currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, YOUNGBLOOD, WILLIAM JUSTIN, who is the busiest examiner with 1 busiest examiner pending office action. The prosecution is focused within 1 distinct art unit, simplifying the technical requirements for the applicant. This allows for a direct response to the matter.
With only 1 pending office action, the prosecution strategy is highly concentrated. The practitioner can focus on the specific concerns of 1 distinct examiner without the need to coordinate across multiple examiners or art units. The presence of 1 distinct art unit ensures that the technical dialogue remains consistent. This focused approach is beneficial for maintaining a clear prosecution history for the pending application. By addressing the 1 busiest examiner pending office action directly, the applicant can navigate the specific requirements of the personnel assigned to the case.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18266294 | Novel Bifunctional Molecules For Targeted Protein Degradation | YOUNGBLOOD, WILLIAM JUSTIN | 139d overdue |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18266294 | Novel Bifunctional Molecules For Targeted Protein Degradation | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §112DP | Non-Final OA | 139d overdue | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial